Morphine produced by the state-owned enterprise Endopharm is now approved for intrathecal administration — directly into the subarachnoid space of the spinal cord.
Endopharm has updated the prescribing information for its Morphine, 10 mg/ml injection solution, to include the intrathecal route of administration. As part of implementing provisions of the “Healthcare Development Strategy in the Russian Federation until 2030,” the company has manufactured the first batches totaling over 150,000 packages, with market release planned for February 2026, the enterprise’s press service reported.
According to Denis Protsenko, Director of the Kommunarka Clinical Center, doctors now have a “long-awaited and effective option” for managing chronic pain and for performing neuraxial anesthesia during surgical procedures. This allows for achieving a “sustained analgesic effect with a lower dose and significantly reduces systemic side effects.”
The intrathecal method ensures rapid absorption and maximum concentration in the cerebrospinal fluid. Its advantages include a fast onset of action, prolonged duration, and reduced frequency of injections. Intrathecal administration is used in neurosurgery, traumatology, neurology, and cardiology. The technology also enables management of chronic pain syndromes in oncology and neurology through the implantation of pumps and ports for continuous micro-dosing.